Gemcitabine/nab-paclitaxel for pediatric relapsed/refractory sarcomas

Area of Science:

• Pediatric Oncology
• Medical Oncology
• Pharmacology

Background:

• Pediatric patients with relapsed/refractory sarcomas face poor prognoses, necessitating novel therapeutic strategies.
• The combination of gemcitabine and nab-paclitaxel has not been previously evaluated in pediatric populations for sarcoma treatment.
• There is a critical need for treatments that control disease while preserving quality of life in young cancer patients.

Purpose of the Study:

• To evaluate the activity and toxicity of gemcitabine and nab-paclitaxel in pediatric patients with relapsed/refractory sarcomas.
• To determine the clinical benefit and safety profile of this combination chemotherapy regimen.
• To assess response rates, progression-free survival, and overall survival in this patient cohort.

Main Methods:

• A retrospective review of 16 pediatric patients (15 relapsed/refractory, 1 treatment-naïve) treated with gemcitabine/nab-paclitaxel was conducted.
• Data on treatment cycles, toxicity (including Grade ≥3 events), transfusions, and clinical responses were analyzed.
• Survival outcomes, including time to progression and overall survival, were calculated.

Main Results:

• Sixteen patients received 53 cycles; 55% had ≥Grade 3 toxicity, primarily hematologic. Non-hematologic Grade ≥3 toxicities occurred in 15% of cycles.
• Clinical benefit (partial response or stable disease ≥4 months) was observed in 31% of patients.
• Median time to progression was 72 days; 4-month progression-free survival was 31%, and 1-year overall survival was 19%.

Conclusions:

• Gemcitabine/nab-paclitaxel is a relatively safe regimen for pediatric sarcomas, with manageable toxicities predominantly hematologic.
• The combination offers a well-tolerated palliative option, providing clinical benefit to a subset of patients.
• A Phase I trial of this combination in pediatric patients is currently ongoing.